Metropolitan Life Insurance Co. NY Buys 2,992 Shares of Corcept Therapeutics Incorporated (CORT)

Metropolitan Life Insurance Co. NY boosted its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 5.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 56,303 shares of the biotechnology company’s stock after buying an additional 2,992 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Corcept Therapeutics were worth $617,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CORT. Teachers Advisors LLC boosted its stake in shares of Corcept Therapeutics by 45.8% in the fourth quarter. Teachers Advisors LLC now owns 184,460 shares of the biotechnology company’s stock worth $1,339,000 after buying an additional 57,985 shares during the period. Trexquant Investment LP bought a new stake in shares of Corcept Therapeutics during the first quarter worth about $202,000. AQR Capital Management LLC boosted its stake in shares of Corcept Therapeutics by 152.7% in the first quarter. AQR Capital Management LLC now owns 359,615 shares of the biotechnology company’s stock worth $3,941,000 after buying an additional 217,323 shares during the period. Prudential Financial Inc. bought a new stake in shares of Corcept Therapeutics during the first quarter worth about $198,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Corcept Therapeutics by 23.3% in the first quarter. Renaissance Technologies LLC now owns 1,858,500 shares of the biotechnology company’s stock worth $20,369,000 after buying an additional 351,000 shares during the period. Institutional investors own 55.96% of the company’s stock.

Shares of Corcept Therapeutics Incorporated (CORT) traded down 0.55% during trading on Friday, hitting $14.52. The company had a trading volume of 653,807 shares. The stock has a market capitalization of $1.65 billion, a P/E ratio of 72.24 and a beta of 2.06. The firm’s 50 day moving average is $13.06 and its 200-day moving average is $10.92. Corcept Therapeutics Incorporated has a 52 week low of $5.24 and a 52 week high of $15.58.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, August 1st. The biotechnology company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. The company had revenue of $35.56 million for the quarter, compared to the consensus estimate of $31.37 million. Corcept Therapeutics had a return on equity of 51.45% and a net margin of 22.28%. The firm’s revenue for the quarter was up 80.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.01 earnings per share. Equities research analysts anticipate that Corcept Therapeutics Incorporated will post $0.43 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/08/19/metropolitan-life-insurance-co-ny-acquires-2992-shares-of-corcept-therapeutics-incorporated-cort-updated.html.

A number of brokerages recently issued reports on CORT. BidaskClub raised Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday. Zacks Investment Research raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating and set a $14.00 price target on the stock in a report on Wednesday, July 19th. Ladenburg Thalmann Financial Services set a $20.00 price target on Corcept Therapeutics and gave the company a “buy” rating in a report on Tuesday, July 18th. TheStreet raised Corcept Therapeutics from a “c+” rating to a “b” rating in a report on Monday, May 22nd. Finally, Piper Jaffray Companies set a $18.00 price target on Corcept Therapeutics and gave the company a “buy” rating in a report on Monday, May 15th. One analyst has rated the stock with a sell rating, three have issued a buy rating and two have given a strong buy rating to the stock. Corcept Therapeutics presently has an average rating of “Buy” and a consensus target price of $14.20.

In related news, Director David L. Mahoney sold 23,006 shares of the business’s stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $12.50, for a total value of $287,575.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David L. Mahoney sold 6,091 shares of the business’s stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $12.50, for a total value of $76,137.50. The disclosure for this sale can be found here. Insiders sold 42,601 shares of company stock worth $532,513 over the last quarter. 19.20% of the stock is owned by company insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

What are top analysts saying about Corcept Therapeutics Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corcept Therapeutics Incorporated and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit